公开(公告)号：US20190194288A1

公开(公告)日：2019-06-27

申请号：US16295978

申请日：2019-03-07

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas BRENNAN ,  David BELLOVIN ,  David BUSHA ,  Barbara SENNINO

IPC: C07K14/705 ,  A61K39/395 ,  A61K38/17 ,  C07K16/00 ,  A61K45/06 ,  C07K16/28

CPC classification number: C07K14/70532 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/00 ,  C07K16/2803 ,  C07K2317/41 ,  C07K2319/03 ,  C07K2319/30

Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

公开(公告)号：US20200255528A1

公开(公告)日：2020-08-13

申请号：US16814627

申请日：2020-03-10

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles KAPLAN ,  Derrick HOUSER ,  Luis BORGES ,  Gloria BRATTICH ,  David BELLOVIN ,  Felicia KEMP ,  Majid GHODDUSI ,  Nels P. NIELSON ,  Kathy MILLER ,  Maike SCHMIDT

IPC: C07K16/28 ,  G01N33/574 ,  A61P35/00

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20240041979A1

公开(公告)日：2024-02-08

申请号：US17742189

申请日：2022-05-11

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Thomas BRENNAN ,  David BELLOVIN ,  Barbara SENNINO ,  David BUSHA

IPC: A61K38/17 ,  C07K16/28 ,  A61P35/00 ,  A61P1/00

CPC classification number: A61K38/1774 ,  C07K16/2818 ,  C07K16/2827 ,  A61P35/00 ,  A61P1/00 ,  A61K2039/505

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20190202889A1

公开(公告)日：2019-07-04

申请号：US16354689

申请日：2019-03-15

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas BRENNAN ,  David BELLOVIN ,  David BUSHA ,  Barbara SENNINO

IPC: C07K14/705 ,  A61K39/395 ,  A61K38/17 ,  C07K16/00 ,  A61K45/06 ,  C07K16/28

CPC classification number: C07K14/70532 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/00 ,  C07K16/2803 ,  C07K2317/41 ,  C07K2319/03 ,  C07K2319/30

Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.